p53 immunostaining predicts chemosensitivity in non-small cell lung cancer: A preliminary report

Cancer Journal from Scientific American

Volumn 2, Issue 4, 1996, Pages 217-220

  Kawasaki, Masayuki ^a   Nakanishi, Yoichi ^a   Yatsunami, Jun ^a   Takayama, Koichi ^a   Ochiai, Sanae ^a   Xinhai, Pei ^a   Kuwano, Kazuyoshi ^a   Hara, Nobuyuki ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Non small cell lung cancer; p53

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; PROTEIN P53; VINDESINE;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PILOT STUDY; PROGNOSIS; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; VINDESINE;

EID: 0000343218     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA Cancer J 1994;44:7-26.
2. Rapp E, Pater JL, Willan A et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6:633-641.
3. Cellerino R, Tummarello D, Guidi F et al. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small cell lung cancer. J Clin Oncol 1991;9:1453-1461.
4. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-967.
5. Kinzler KW, Vogelstein B. Cancer therapy meets p53. N Engl J Med 1994;331:49-50.
6. Takahashi T, Nau MM, Chiba I et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989;246:491-494.
7. Iggo R, Catter K, Bartek J, Lane D, Harris AD. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675-679.
8. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992;256:827-830.
9. Farmer G, Bargonetti J, Zhu H et al. Wild-type p53 activates transcription in vitro. Nature 1992;358:83-86.
10. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppresser gene. N Engl J Med 1993;329:1318-1327.
11. Brown R, Clugston C, Burns P et al. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 1993;55:678-684.
12. Lee JM, Bernstein A. p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 1993;90:5742-5746.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting the results of cancer treatment. Cancer 1981;47:207-214.
14. Shin RW, Iwaki T, Kitamoto T, Tateishi J. Hydrated autoclave pretreatment enhances TAU immunoreactivity in formalin-fixed normal and Alzheimer's disease brain tissues. Lab Invest 1991; 64:693-702.
15. Fan S, El-Deiry WS, Bae I et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994;54:5824-5830.
16. Fujiwara T, Grimm EA, Mukhopadhyay T, Zang W-W, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994;54:2287-2291.
17. Lowe SW, Bodis S, McClatchey A et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-810.
18. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with poor prognosis in human lung cancer. Cancer Res 1992;52:4828-4831.
19. Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R, Shirakusa T. Mutation of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst 1993;85:2018-2023.
20. Brambilla E, Gazzeri S, Moro D et al. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 1993; 143:199-210.
21. Passlick B, Izabicki JR, Riethüller G, Pautel K. p53 in non-small-cell lung cancer [letter]. J Natl Cancer Inst 1994;86:801-802.